2-(3-(2,4-二氟苯基)-4,5-二氢异恶唑-5-基)-1-吗啉乙酮
2-(3-(2,4-二氟苯基)-4,5-二氢异恶唑-5-基)-1-吗啉乙酮 性质
| 沸点 | 453.3±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.40±0.1 g/cm3(Predicted) |
| 储存条件 | Store at -20°C |
| 溶解度 | DMSO:22.34(最大浓度 mg/mL);71.99(最大浓度 mM) DMSO:PBS (pH 7.2) (1:4):0.2(最大浓度 mg/mL);0.64(最大浓度. mM) DMF:30.0(最大浓度 mg/mL);96.68(最大浓度 mM) 乙醇:3.1(最大浓度 mg/mL);9.99(最大浓度 mM) |
| 形态 | 结晶固体 |
| 酸度系数(pKa) | -0.91±0.20(Predicted) |
| 颜色 | 白色至米白色 |
2-(3-(2,4-二氟苯基)-4,5-二氢异恶唑-5-基)-1-吗啉乙酮 用途与合成方法
MIF.
Mice treated with CPSI-1306 show a significant drop in their blood glucose levels, which is associated with a reduction in serum levels of inflammatory cytokines. As expected, control mice treated with vehicle develop NIDDM as characterized by high serum levels of glucose and inflammatory cytokine. Furthermore, they also show that orally bioavailable CPSI-1306 can be effective in treating this disease. CPSI-1306-induced keratinocyte apoptosis could be appreciated as early as 30 minutes after a single UVB exposure. At 6, 24, and 48 hours following UVB exposure, the CPSI-1306-treated mice show significantly increased expression of cleaved caspase-3 compared with the vehicle-treated mice. CPSI-1306 reduces acute UVB-induced keratinocyte DNA damage and UVB-induced acute inflammation.
